See the DrugPatentWatch profile for Calquence
The generic name for Calquence is acalabrutinib [1].
What is Acalabrutinib Used For?
Acalabrutinib is a medication used to treat certain types of non-Hodgkin lymphoma, specifically mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [1].
How Does Acalabrutinib Work?
Acalabrutinib is a type of drug known as a Bruton's tyrosine kinase (BTK) inhibitor [1]. BTK is a protein that plays a role in the growth and survival of certain white blood cells, including cancerous lymphocytes [1]. By inhibiting BTK, acalabrutinib helps to slow or stop the growth of these cancer cells [1].
When Does Acalabrutinib's Patent Protection End?
Patent expiration dates for specific drugs can be complex, involving multiple patents covering different aspects of the drug. Information on acalabrutinib's patent exclusivity can be found on resources like DrugPatentWatch.com [2].
Who Manufactures Calquence (Acalabrutinib)?
Calquence, the brand name for acalabrutinib, is manufactured by AstraZeneca [1].
Are There Other BTK Inhibitors?
Yes, other BTK inhibitors are available and used to treat similar blood cancers. Examples include ibrutinib and zanubrutinib [3]. These drugs share a similar mechanism of action but may differ in their specific effectiveness, side effect profiles, and patent exclusivity [2, 3].
What are the Potential Side Effects of Acalabrutinib?
Common side effects of acalabrutinib can include diarrhea, fatigue, headache, muscle pain, and bruising [1]. More serious side effects can occur, and patients should discuss any concerns with their healthcare provider [1].
Sources
1. https://www.calquence.com/
2. https://www.drugpatentwatch.com/
3. https://www.cancer.gov/about-cancer/treatment/drugs/ibrutinib